|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0030705,
umls-concept:C0045093,
umls-concept:C0205195,
umls-concept:C0205314,
umls-concept:C0442027,
umls-concept:C0526371,
umls-concept:C0679622,
umls-concept:C0684249,
umls-concept:C0915830,
umls-concept:C0920321,
umls-concept:C1514555
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-2-4
|
|
pubmed:abstractText |
PKC412 (N-benzoyl-staurosporine), an oral inhibitor of protein kinase C, is capable of cell cycle inhibition and is endowed with anti-angiogenic properties. This dose-finding phase I study was designed to establish the maximum tolerated dose (MTD) of PKC412 when combined with cisplatin-gemcitabine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
316-23
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14760128-Administration, Oral,
pubmed-meshheading:14760128-Adult,
pubmed-meshheading:14760128-Aged,
pubmed-meshheading:14760128-Angiogenesis Inhibitors,
pubmed-meshheading:14760128-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14760128-Asthenia,
pubmed-meshheading:14760128-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:14760128-Cisplatin,
pubmed-meshheading:14760128-Deoxycytidine,
pubmed-meshheading:14760128-Diarrhea,
pubmed-meshheading:14760128-Enzyme Inhibitors,
pubmed-meshheading:14760128-Female,
pubmed-meshheading:14760128-Humans,
pubmed-meshheading:14760128-Infusions, Intravenous,
pubmed-meshheading:14760128-Lung Neoplasms,
pubmed-meshheading:14760128-Male,
pubmed-meshheading:14760128-Maximum Tolerated Dose,
pubmed-meshheading:14760128-Middle Aged,
pubmed-meshheading:14760128-Protein Kinase C,
pubmed-meshheading:14760128-Staurosporine
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
